A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol (ACTFAST SWISS)

Viatris

Status and phase: Completed; Phase 3

Conditions: Hyperlipidemia

Treatments: Drug: Atorvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00136942

A2581089

Details and patient eligibility

About

The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
• LDL-C < 6.0 mmol/l
• Triglyceride level < 5.0 mmol/l.

Exclusion criteria

• Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)